Back to dendritic cell vaccine

dendritic cell vaccine

Showing 1 study arm with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	median follow-up [months]⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Rodríguez-Ruiz et al.	2018	Prospective	Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients	10.1093/annonc/mdy089	—	6	54	Missing	Prostate cancer, Head and neck cancer, other	any	Therapeutic Vaccines	dendritic cell vaccine	dendritic cell vaccines, and hiltonol intratumoral injection	6	extra-cranial	lung, liver, LN unspecified, other	peritoneum node, also other sites irradiated but not specified (only specified sites are those that received Hiltonol and SBRT)	24	24	24	3	3	3	8	8	8	Treatment-rel.	—	—	0	—	—	—	—